Breaking News
Get 50% Off 0
🧩 Based on my current watchlist, how should I diversify my portfolio?
Ask WarrenAI
Close

NewAmsterdam Pharma Company NV (NAMS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow NewAmsterdam Pharma's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
24.520 +1.560    +6.79%
18:48:04 - Real-time Cboe. Currency in USD
Type:  Equity
Market:  United States
  • Volume: 1,255,239
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 23.230 - 25.850
NewAmsterdam Pharma 24.520 +1.560 +6.79%

NewAmsterdam Pharma Company NV Company Profile

 
Get an in-depth profile of NewAmsterdam Pharma Company NV, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

68

Equity Type

ORD

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Contact Information

Address Gooimeer 2-35
Naarden, 1411 DC
Netherlands
Phone 31 35 206 2971
Fax -

Top Executives

Name Age Since Title
John W. Smither 70 2023 Independent Director
Michael Harvey Davidson 67 2020 CEO, President, Executive Board Member & Director
William H. Lewis 55 2024 Independent Chairman of Board of Directors
Alberico Catapano - - Member of Clinical Advisory Board
Ulrich Laufs - - Member of Clinical Advisory Board
Steven E. Nissen - - Member of Clinical Advisory Board
Maciej Banach - - Member of Clinical Advisory Board
Roxana Mehran - - Member of Clinical Advisory Board
James Newman Topper 63 2022 Non-Executive Director
Hilde Johanna van der Kamp 48 2023 Independent Non-Executive Director
Stephen Nicholls - - Member of Clinical Advisory Board
Mark C. McKenna 44 2024 Non-Executive Vice Chairman
Brian Ference - - Member of Clinical Advisory Board
Louis G. Lange 76 2022 Independent Non-Executive Director
Ann Marie Navar - - Member of Clinical Advisory Board
Christie Mitchell Ballantyne - - Member of Clinical Advisory Board
Johannes Jacob Pieter Kastelein 71 2020 Founder, Chief Scientific Officer, Member of Executive Board & Director
Wouter Joustra 36 2024 Non-Executive Director
Nicholas S. Downing 39 2022 Independent Non-Executive Director
Kosh Ray - - Member of Clinical Advisory Board
Adele M. Gulfo 62 2025 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NAMS Comments

Write your thoughts about NewAmsterdam Pharma Company NV
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email